Research Advance on the Role of Spleen Tyrosine Kinase Inhibitors in Hematologic Malignancies / 中国实验血液学杂志
Journal of Experimental Hematology
; (6): 1054-1058, 2020.
Article
in Zh
| WPRIM
| ID: wpr-827162
Responsible library:
WPRO
ABSTRACT
Abstract Spleen tyrosine kinase (SYK) is not only a key kinase in the B-cell receptor (BCR) signaling pathway, but also a critical component of other signal transduction pathways such as Fc receptor, complement receptor and integrin. Abnormal activation of SYK closely related to the occurrence and development of hematological malignancies, thus targeting SYK has become a research hotspot. Several SYK inhibitors including Fostamatinib, Entospletinib and Cerdulatinib were being evaluated in clincal trials. As a second generation SYK inhibitor, Entospletinib has achieved good efficacy in lymphoid and myeloid hematologic tumors. Furthermore, Entospletinib can significantly relieve hematopoietic stem cell transplantation(HCT) related graft versus host disease (GVHD). In this review the role of SYK inhibitors in treatment of hematological malignancies is summarized brifely.
Full text:
1
Database:
WPRIM
Main subject:
Spleen
/
Hematologic Neoplasms
/
Protein Kinase Inhibitors
/
Syk Kinase
/
Graft vs Host Disease
Limits:
Humans
Language:
Zh
Journal:
Journal of Experimental Hematology
Year:
2020
Type:
Article